Melanoma Advances Improved OS in Patients With Brain Mets

Source: Medscape, July 2020

Advances that emerged from 2007 – 2016 in the treatment of melanoma, including targeted agents, immunotherapy, and new radiotherapy techniques, led to significant improvement in overall survival for patients with melanoma and brain metastases, according to findings from a large population-based cohort study.

The 2-year survival rate doubled during that period, the researchers note: it was 13.8% for patients treated from 2013 – 2016, compared to 6.4% for patients treated from 2007 – 2009 (adjusted hazard ratio for the 2-year survival comparison, 0.65).

The study included 1096 melanoma patients who underwent radiotherapy, surgical excision, or both for brain metastases in Ontario, Canada, between January 1, 2007, and June 30, 2016.

READ THE ORIGINAL FULL ARTICLE